Friday, TD (TSX:TD) Cowen maintained a Hold rating on BioNTech (NASDAQ:BNTX) shares with a price target of $85.00. The decision followed an announcement from Pfizer/BioNTech regarding their phase 3 trial of a combined flu and COVID-19 mRNA vaccine.
The trial, which involved over 8,000 healthy volunteers, aimed to meet two primary immunogenicity objectives. However, the vaccine succeeded in only one, failing to exhibit non-inferiority against the influenza B strain.
Despite this, the vaccine showed a trend of higher responses to influenza A compared to a licensed flu vaccine and maintained comparable responses to Pfizer/BioNTech's approved COVID-19 vaccine.
The safety and tolerability of the combo vaccine were deemed satisfactory, which was a significant concern given the combination of multiple mRNA vaccines. Pfizer/BioNTech are now evaluating ways to enhance the vaccine's efficacy against influenza B and plan to consult with regulatory authorities regarding future adjustments.
The outcome of the trial was seen as a setback for BioNTech's ambitions to expand its COVID-19 vaccine business. Nonetheless, Pfizer (NYSE:PFE)'s second-generation standalone mRNA flu vaccine has demonstrated strong responses in a phase 2 trial for both influenza A and B.
TD Cowen's assessment reflects the unchanged investment thesis for BioNTech, noting that the firm does not account for royalties from the flu/COVID-19 combo vaccine in its financial model. The focus for BioNTech is increasingly shifting towards its oncology pipeline, with management aiming to initiate at least 10 pivotal studies by the end of 2024 and introduce several new products to the market between 2026 and 2027.
In other recent news, BioNTech has experienced various shifts in stock targets and ratings from different firms. BMO (TSX:BMO) Capital maintained its Outperform rating on BioNTech, with a price target of $122, following the outcomes of a Phase 3 trial evaluating BioNTech's combined mRNA vaccine for influenza and COVID-19.
TD Cowen reduced its price target for BioNTech to $85 due to lower second-quarter revenue, yet retained its Hold rating. Morgan Stanley (NYSE:MS) also reduced its price target for BioNTech to $93, attributing the change to increased operational expenses.
BioNTech experienced a widening net loss in the second quarter, reaching 807.8 million euros. This was primarily due to a 23% decline in quarterly revenue, largely attributed to reduced sales of its COVID-19 vaccine. Despite these financial results, the company's finance chief, Jens Holstein, expressed confidence in BioNTech's long-term growth strategies.
BioNTech is shifting its focus towards its oncology pipeline. The company plans to release key updates on several cancer drugs, including Phase 1/2 data for BNT113 in HPV16-induced carcinomas, BNT327 in renal cell carcinoma, and BNT211 in CLDN6-positive tumors.
This shift in focus led HSBC to upgrade BioNTech's stock from Hold to Buy. Furthermore, BioNTech and DualityBio received Fast Track designation from the FDA for their investigational drug, BNT324/DB-1311, for treating patients with metastatic castration-resistant prostate cancer.
InvestingPro Insights
In light of TD Cowen's Hold rating on BioNTech and the recent developments in their vaccine trials, current data from InvestingPro provides further context for investors. BioNTech's market capitalization stands at $20.24 billion, reflecting a significant presence in the biotechnology market. Despite recent setbacks, one InvestingPro Tip highlights that the company holds more cash than debt, indicating a strong balance sheet that could support future research and development efforts. Additionally, BioNTech's aggressive share buyback strategy, as noted in another InvestingPro Tip, suggests confidence from management in the company's value proposition.
From a valuation perspective, BioNTech's price-to-book ratio as of the last twelve months leading into Q2 2024 is 0.96, which could suggest that the stock is reasonably valued in terms of its net assets. However, a P/E ratio of -36.54 and an adjusted P/E ratio of -40.16 reflect the current earnings challenges faced by the company. The InvestingPro data also shows a significant revenue decline of 70.7% over the last twelve months as of Q2 2024, aligning with analysts' expectations of a sales decline in the current year. This is particularly relevant as BioNTech pivots its focus towards its oncology pipeline, which could be critical for future growth.
For investors seeking more in-depth analysis and additional insights, there are over 10 InvestingPro Tips available, which can be accessed on InvestingPro's platform for BioNTech. These tips may offer a more nuanced understanding of the company's financial health and market potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.